Table 2.
Immunohistochemical (IHC) profile for select markers and secondary cancers and infections.
| Positive staining | FDCS n = 31 |
HS n = 15 |
IDCS n = 7 |
|---|---|---|---|
| CD35 | 26/28 | 1/4 | 1/4 |
| CD21 | 22/26 | 0/7 | 0/4 |
| S-100 | 9/18 | 8/12 | 7/7 |
| CD68 | 4/6 | 15/15 | 4/5 |
| Clusterin | 4/5 | – | 1/2 |
| CD163 | – | 7/7 | 0/1 |
| Lysozyme | 0/1 | 4/6 | 1/2 |
| CD1a | – | 0/8 | 0/3 |
| Vimentin | 11/12 | 4/4 | 3/3 |
| EMA | 4/10 | 0/2 | 0/1 |
| HLA-DR | – | – | – |
| CD45 | 0/4 | 5/5 | 1/2 |
| Other Neoplasms (Age at diagnosis of other neoplasms, Age at diagnosis of FDCS or HS) | |||
| Lymphoma | Hodgkin lymphoma | Diffuse large B cell lymphoma (37, 37) Chronic lymphocytic leukaemia (76, 76) Marginal zone lymphoma (51, 54) Follicular lymphoma (76, 76) |
|
| Solid tumours | Melanoma (43, 53; 39, 34) Uterine (56, 72) Endometrial (53, 57) Transitional cell (64, 72; 69, 82) Breast (47, 53) Gastric (NA, 71) Laryngeal (NA, 82) Papillary thyroid (49, 49) Hurthle cell thyroid (47, 44) |
Bladder (40, 50) Melanoma (60, 57) |
|
| Infections | Castleman disease (n = 2) | HIV/AIDS (n = 1) | – |
| Other | Multiple scrotal and cutaneous lipomas | Sarcoidosis | – |
FDCS, follicular dendritic cell sarcoma; HS, histiocytic sarcoma; IDCS, interdigitating dendritic cell sarcoma; CNS, central nervous system; NA, not available.